Effect of other medicinal products on Veraxanib
Veraxanib is primarily metabolised by CYP3A4. Concomitant use of strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, St. John's Wort [Hypericum perforatum]) is contraindicated as they significantly decrease veraxanib exposure (see section 4.3). Caution is advised with moderate CYP3A4 inducers; close monitoring for reduced efficacy is recommended.
Concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin) may increase veraxanib exposure. Use with caution and consider dose reduction if toxicity occurs.
Effect of Veraxanib on other medicinal products
In vitro data suggest veraxanib is a weak inhibitor of CYP2D6. Caution should be exercised when co-administering medicinal products that are CYP2D6 substrates with a narrow therapeutic index (e.g. certain antidepressants, antipsychotics).
Veraxanib may reduce the efficacy of oral hormonal contraceptives. Non-hormonal or additional contraceptive measures should be used concurrently and for at least one month after stopping Veraxanib (see section 4.6).
Effect of other medicinal products on Veraxanib
Veraxanib is primarily metabolised by CYP3A4. Concomitant use of strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, St. John's Wort) is contraindicated as they significantly decrease veraxanib exposure (see section 4.3). Caution is advised with moderate CYP3A4 inducers; close monitoring for reduced efficacy is recommended.
Concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin) may increase veraxanib exposure. Use with caution and consider dose reduction if toxicity occurs.
Effect of Veraxanib on other medicinal products
In vitro data suggest veraxanib is a weak inhibitor of CYP2D6. Caution should be exercised when co-administering medicinal products that are CYP2D6 substrates with a narrow therapeutic index (e.g. certain antidepressants, antipsychotics).
Veraxanib may reduce the efficacy of oral hormonal contraceptives. Non-hormonal or additional contraceptive measures should be used (see section 4.6).
Effect of other medicinal products on Veraxanib
Veraxanib is primarily metabolised by CYP3A4. Concomitant use of strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine) is contraindicated as they significantly decrease veraxanib exposure (see section 4.3). Caution is advised with moderate CYP3A4 inducers.
Concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin) may increase veraxanib exposure. Use with caution and consider dose reduction if toxicity occurs.
Effect of Veraxanib on other medicinal products
In vitro data suggest veraxanib is a weak inhibitor of CYP2D6. Caution should be exercised when co-administering medicinal products that are CYP2D6 substrates with a narrow therapeutic index.